Clinical trials in Africa have moved from a niche consideration to a strategic priority for sponsors facing pressure to diversify trial populations and reduce per-patient costs. The continent carries roughly 24 percent of the global disease burden, hosts some of the world's largest treatment-naive patient populations, and offers site activation costs that can run 30 to 50 percent below equivalent sites in North America or Western Europe. For sponsors building out global development programmes, especially those responding to FDA diversity action plan requirements, Africa is no longer optional. This guide covers what sponsors and CROs need to know about conducting clinical research on the continent: regulatory frameworks, site infrastructure, patient recruitment advantages, data systems, and operational realities.
Why sponsors are looking to Africa for clinical research
Several factors are making Africa more attractive for clinical research. Regulatory pressure is one. The Food and Drug Omnibus Reform Act of 2022 (FDORA) requires sponsors to submit Diversity Action Plans when initiating Phase 3 or other pivotal trials, and the FDA's epidemiology-based approach to enrollment targets means conditions with high African-ancestry prevalence (type 2 diabetes, hypertension, sickle cell disease, HIV, hepatitis B, several cancers) may require African-site enrollment to demonstrate adequate representation.
Scientific necessity is another driver. African populations harbour more genetic variation than any other single global region, and pharmacogenomic profiles differ in ways that matter clinically. CYP450 enzyme variants that affect drug metabolism show frequencies in African-ancestry populations that differ substantially from European cohorts. Sponsors who conduct trials without African participants are generating incomplete safety and efficacy data. The diversity in clinical trials imperative is, at its core, a scientific argument.
Economics is the third factor. Treatment-naive patient pools, high disease prevalence, and lower site infrastructure costs allow sponsors to enroll more patients faster and at lower cost than in saturated Western markets. Industry reporting suggests that some African sites report screen failure rates substantially below rates at US sites for the same indication, in some cases by 40 to 60 percent, because patients have had less prior exposure to investigational therapies, though figures vary considerably by therapeutic area and site.
Clinical trial sites in Africa: where research happens
Clinical trial sites in Africa are concentrated in a handful of countries with established research infrastructure. South Africa, Nigeria, Kenya, Ghana, Ethiopia, Uganda, and Tanzania each have a significant number of registered trial sites, with South Africa accounting for the largest share of Phase III registrational trial activity on the continent.
South Africa's research infrastructure is the most developed. Sites including the Wits Reproductive Health and HIV Institute (Wits RHI), the South African Medical Research Council (SAMRC) facilities, and the Perinatal HIV Research Unit (PHRU) in Soweto have participated in landmark trials across HIV, TB, oncology, and vaccines. The country's SAHPRA (South African Health Products Regulatory Authority) is recognised as one of the continent's most capable regulatory agencies.
East Africa has particular strength in infectious disease research. Kenya hosts the KEMRI-Wellcome Trust Research Programme, one of the continent's leading clinical research organisations, with established trial capacity in malaria, HIV, TB, and vaccine science. Uganda's Makerere University-based research programmes have contributed to major HIV and TB trials. Tanzania's Muhimbili National Hospital and associated research units provide capacity for both infectious disease and non-communicable disease trials.
West Africa's capacity is growing rapidly. Nigeria has invested in research infrastructure under the Pharmaceutical Society of Nigeria and the West African Health Organisation (WAHO) frameworks. Ghana's Noguchi Memorial Institute and Komfo Anokye Teaching Hospital have conducted multi-country trials. Rwanda, though smaller, has built a reputation for operational excellence in health systems research and vaccine trials, driven by strong government coordination.
Sponsors seeking sites in any of these countries should work with experienced local CROs or site management organisations (SMOs) who understand local ethics review processes, community engagement requirements, and logistical constraints.
Regulatory frameworks and GCP compliance in Africa
GCP compliance in Africa is not uniform. Regulatory capacity, ethics review timelines, and inspection standards vary significantly across jurisdictions, and sponsors need to assess each country individually.
South Africa's SAHPRA conducts GCP inspections and has mutual recognition agreements with several international regulators. Clinical trial authorisation through SAHPRA typically takes 2 to 3 months, with initial screening completed within 3 weeks and committee recommendations within approximately 10 weeks. The country follows ICH E6 GCP guidelines directly and has a functioning pharmacovigilance system.
NAFDAC (Nigeria's National Agency for Food and Drug Administration and Control) has been strengthening its clinical trial review process, with a maximum timeline of 60 working days (approximately 3 months) for trial authorisation. NAFDAC has pursued capacity-building partnerships with the US FDA and EMA. The Nigerian National Health Research Ethics Committee (NHREC) coordinates a network of institutional review boards, though timelines vary.
The Pharmacy and Poisons Board (PPB) and the National Commission for Science, Technology and Innovation (NACOSTI) regulate clinical trials in Kenya. The Kenya Medical Research Institute (KEMRI) has GCP-certified facilities and has been involved in Phase I through Phase III trials. Ethiopia's Food and Drug Administration (EFDA), formerly EFMHACA, has been expanding its regulatory capacity with WHO support.
The African Vaccine Regulatory Forum (AVAREF) coordinates regulatory reviews for vaccine trials across multiple African countries simultaneously, reducing timelines for multi-country submissions from years to months. This model of joint review is being explored for non-vaccine trials as well.
For effective patient recruitment across African sites, sponsors should budget for longer ethics review timelines than in Western markets (typically 3 to 9 months for multi-site studies) and engage local regulatory consultants early.
Patient recruitment advantages on the continent
Africa's patient recruitment profile differs from Western markets in ways that benefit sponsors in certain therapeutic areas.
Treatment-naive populations are available at scale. For conditions where prior therapy confounds efficacy signals, Africa offers patient pools with limited prior drug exposure. HIV treatment-naive cohorts, for example, are far more available in East and West African countries than in the US or Europe, where most HIV-positive patients are already on antiretroviral therapy.
Disease burden is high across many indications. Conditions including diabetes (affecting an estimated 24 million adults in the IDF Africa region, according to the IDF Diabetes Atlas 2021), hypertension, malaria, TB, hepatitis B, sickle cell disease, and several cancers have much higher prevalence than in developed-market populations. Large eligible patient pools translate to faster enrollment and lower screen failure rates.
Participants tend to be younger and have fewer cardiovascular comorbidities than Western cohorts, which benefits some oncology and metabolic disease trials where comorbidity exclusions are common.
Community engagement can be higher in settings where clinical trial participation gives access to treatments and monitoring that participants could not otherwise obtain. Participation rates improve when trials are well-explained and community trust is established.
The challenge is that community trust must be earned, not assumed. The history of research ethics violations in Africa, real and perceived, means that informed consent processes require more time and care than in Western settings, and community advisory boards are not optional.
Data infrastructure supporting clinical research in Africa
The quality of clinical research in Africa depends on the quality of the underlying data infrastructure. This has been a persistent concern, but the situation is improving faster than many Western sponsors realise.
Electronic health record adoption has expanded substantially across East and West Africa. OpenMRS is deployed across thousands of facilities in Kenya, Uganda, Rwanda, Ethiopia, Nigeria, and Ghana. KenyaEMR, built on OpenMRS, is the national standard for HIV clinic data in Kenya and is deployed across over 2,300 health facilities. Rwanda has been rolling out OpenMRS implementation, coordinated by the Rwanda Biomedical Centre and Partners in Health, with expansion across public-sector facilities. DHIS2 is used for aggregate health data management across dozens of African countries, with national-scale deployments in over a dozen nations including Kenya, Nigeria, Uganda, Rwanda, Ghana, and Tanzania.
Helium Health provides cloud-based EMR, billing, and analytics tools to hospitals in Nigeria and across West Africa, generating structured clinical data that can support trial feasibility analysis, site identification, and post-trial real-world evidence generation.
Kapsule aggregates de-identified records from facilities running these and other systems, covering over 75 million patients across 9 African countries. This kind of structured data allows sponsors to conduct feasibility analyses, model patient eligibility, and identify optimal site locations before committing to site activation, reducing the risk of entering a new research geography.
The growth of digital health infrastructure across the continent is accelerating data quality improvements. Sponsors should no longer approach African site selection assuming they will encounter only paper records; structured electronic data is increasingly available, particularly in urban and peri-urban facilities.
Operational considerations for sponsors and CROs
Running clinical research in Africa requires operational adjustments that sponsors experienced only in North America or Europe will find unfamiliar. Several factors consistently determine success or failure.
Local CRO and SMO selection matters enormously. Experienced local partners (IQVIA Africa, Parexel Africa, or locally-founded CROs with site networks in specific countries) are essential. A CRO without deep relationships with local IRBs, regulatory bodies, and community organisations will struggle regardless of its global capabilities.
Supply chain management requires careful planning, particularly for biologic investigational products. In Nigeria, intermittent power supply means backup generators and temperature monitoring are mandatory. In East Africa, supply chains for smaller countries like Uganda or Rwanda depend on hub facilities in Nairobi or Kigali.
Site staff training and retention is a documented challenge. GCP training programmes need to be ongoing. Sponsors should invest in site capacity development rather than treating African sites as temporary resources.
Community and government engagement is not optional. Successful trials require active engagement with local health ministries, community leaders, and patient advocacy organisations. Studies perceived as extractive face resistance. Benefit-sharing agreements, local publication authorship, and post-trial access commitments are expected.
Currency and payment logistics add complexity in multi-country trials. Several African currencies are subject to exchange controls, and delayed payments are a leading cause of site disengagement.
A practical roadmap for sponsors entering Africa
For sponsors conducting their first African trial, a phased approach reduces risk:
- Feasibility phase: Use structured patient data (from EHR platforms or health data aggregators) to model eligible patient populations by country and disease profile. Identify countries where disease burden, regulatory capacity, and site infrastructure align with the trial's needs.
- Regulatory scoping: Engage a regulatory consultant with specific experience in the target countries to map approval timelines, ethics requirements, and import licences for investigational product. Budget 6 to 12 months for full regulatory approval in most African jurisdictions.
- Site selection: Partner with a local CRO or SMO to conduct site qualification visits. Prioritise sites with GCP training records, existing IRB relationships, and EMR systems that can support source data verification.
- Community engagement: Before site activation, engage community advisory boards and local health authorities. Develop informed consent materials in local languages, tested for comprehension.
- Enrollment monitoring: Build demographic tracking into the clinical trial management system and conduct monthly enrollment reviews against targets. African sites, like all sites, need active monitoring and support when enrollment falls behind.
Africa is not a single clinical research market; it is 54 distinct regulatory environments, each with its own strengths and challenges. Sponsors who treat it as such, investing in country-specific expertise and local partnerships, consistently report that African sites perform as well or better than equivalent sites elsewhere. Those who approach it as a monolithic low-cost option typically encounter the operational complexity without capturing the scientific or economic benefits.
Kapsule provides access to structured, de-identified health records covering over 75 million patients across 9 African countries. Contact our team to discuss how real-world patient data from African facilities can support your clinical trial site selection and feasibility analysis.
This article is intended for informational purposes only and does not constitute legal, medical, or regulatory advice. Readers should obtain independent professional counsel for their specific circumstances.